Literature DB >> 19299404

Plasma urate and Parkinson's disease in the Atherosclerosis Risk in Communities (ARIC) study.

Honglei Chen1, Thomas H Mosley, Alvaro Alonso, Xuemei Huang.   

Abstract

Higher plasma urate concentration has been linked to lower risk of Parkinson's disease in men, but data are lacking on women and African Americans. The authors examined plasma urate in relation to Parkinson's disease in the biracial, population-based Atherosclerosis Risk in Communities (ARIC) cohort. Between 1987 and 1989, 15,792 participants, aged 45-64 years, were recruited from 4 US communities and have since been followed with 3 triennial visits and annual surveillance. Plasma urate was measured at visits 1 and 2, and the concentrations were highly correlated. From visit 1 through 2004, 95 potential cases of Parkinson's disease were identified from multiple sources. Odds ratios and 95% confidence intervals were calculated from multivariate logistic regression models. Plasma urate concentration was inversely associated with Parkinson's disease occurrence. The odds ratios between extreme quartiles of plasma urate were 0.4 (95% confidence interval: 0.2, 0.8) in the overall analysis, 0.3 (95% confidence interval: 0.1, 0.7) for men, and 0.4 (95% confidence interval: 0.2, 1.0) for Caucasians. Such an association was also suggested among women and African Americans but was not statistically significant because of small sample sizes. These data support the previous finding that urate may be a protective factor against Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299404      PMCID: PMC2727240          DOI: 10.1093/aje/kwp033

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  25 in total

Review 1.  Clinical practice. Gout.

Authors:  Robert A Terkeltaub
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

2.  Pesticide exposure and self-reported Parkinson's disease in the agricultural health study.

Authors:  F Kamel; Cm Tanner; Dm Umbach; Ja Hoppin; McR Alavanja; A Blair; K Comyns; Sm Goldman; M Korell; Jw Langston; Gw Ross; Dp Sandler
Journal:  Am J Epidemiol       Date:  2006-11-20       Impact factor: 4.897

Review 3.  Uric acid and oxidative stress.

Authors:  G K Glantzounis; E C Tsimoyiannis; A M Kappas; D A Galaris
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

4.  Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis Risk in Communities.

Authors:  C Iribarren; A R Folsom; J H Eckfeldt; P G McGovern; F J Nieto
Journal:  Ann Epidemiol       Date:  1996-07       Impact factor: 3.797

5.  Observations on serum uric acid levels and the risk of idiopathic Parkinson's disease.

Authors:  J W Davis; A Grandinetti; C I Waslien; G W Ross; L R White; D M Morens
Journal:  Am J Epidemiol       Date:  1996-09-01       Impact factor: 4.897

6.  Serum uric acid levels and the risk of Parkinson disease.

Authors:  Lonneke M L de Lau; Peter J Koudstaal; Albert Hofman; Monique M B Breteler
Journal:  Ann Neurol       Date:  2005-11       Impact factor: 10.422

7.  Serum cholesterol levels and the risk of Parkinson's disease.

Authors:  Lonneke M L de Lau; Peter J Koudstaal; Albert Hofman; Monique M B Breteler
Journal:  Am J Epidemiol       Date:  2006-08-11       Impact factor: 4.897

8.  Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study.

Authors:  J H Eckfeldt; L E Chambless; Y L Shen
Journal:  Arch Pathol Lab Med       Date:  1994-05       Impact factor: 5.534

Review 9.  Nitric oxide and reactive oxygen species in Parkinson's disease.

Authors:  Kim Tieu; Harry Ischiropoulos; Serge Przedborski
Journal:  IUBMB Life       Date:  2003-06       Impact factor: 3.885

10.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

View more
  74 in total

1.  Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease.

Authors:  Anil Kachroo; Michael A Schwarzschild
Journal:  Brain Res       Date:  2014-03-26       Impact factor: 3.252

2.  Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations.

Authors:  Richard J Johnson; Miguel A Lanaspa; Eric A Gaucher
Journal:  Semin Nephrol       Date:  2011-09       Impact factor: 5.299

3.  Parkinson's disease research in a prospective cohort in China.

Authors:  Honglei Chen; Ding Ding; Jian Wang; Qianhua Zhao; Haijiao Meng; Honglan Li; Yu-Tang Gao; Xiao-Ou Shu; Caroline M Tanner; Zhen Hong; Gong Yang
Journal:  Parkinsonism Relat Disord       Date:  2015-08-20       Impact factor: 4.891

4.  Diabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study.

Authors:  Marianthi-Anna Kioumourtzoglou; Ran S Rotem; Ryan M Seals; Ole Gredal; Johnni Hansen; Marc G Weisskopf
Journal:  JAMA Neurol       Date:  2015-08       Impact factor: 18.302

5.  The risk of Parkinson disease associated with urate in a community-based cohort of older adults.

Authors:  S Jain; T G Ton; R M Boudreau; M Yang; E L Thacker; S Studenski; W T Longstreth; E S Strotmeyer; A B Newman
Journal:  Neuroepidemiology       Date:  2011-06-16       Impact factor: 3.282

Review 6.  Drug Repurposing in Parkinson's Disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  CNS Drugs       Date:  2018-08       Impact factor: 5.749

7.  Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis.

Authors:  Éilis J O'Reilly; Kjetil Bjornevik; Michael A Schwarzschild; Marjorie L McCullough; Laurence N Kolonel; Loic Le Marchand; Joann E Manson; Alberto Ascherio
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-12-26       Impact factor: 4.092

Review 8.  Targeting urate to reduce oxidative stress in Parkinson disease.

Authors:  Grace F Crotty; Alberto Ascherio; Michael A Schwarzschild
Journal:  Exp Neurol       Date:  2017-06-13       Impact factor: 5.330

9.  Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial.

Authors:  Michael A Schwarzschild; Eric A Macklin; Rachit Bakshi; Shamik Battacharyya; Robert Logan; Alberto J Espay; Albert Y Hung; Grace Bwala; Christopher G Goetz; David S Russell; John L Goudreau; Sotirios A Parashos; Marie H Saint-Hilaire; Alice Rudolph; Joshua M Hare; Gary C Curhan; Alberto Ascherio
Journal:  Neurology       Date:  2019-09-04       Impact factor: 9.910

10.  Association of perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) with uric acid among adults with elevated community exposure to PFOA.

Authors:  Kyle Steenland; Sarah Tinker; Anoop Shankar; Alan Ducatman
Journal:  Environ Health Perspect       Date:  2010-02       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.